Copyright © 2014 University of York.
Bookshelf ID: NBK179913
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
Show detailsBibliographic details: Martinez-Vazquez MA, Vazquez-Elizondo G, Gonzalez-Gonzalez JA, Gutierrez-Udave R, Maldonado-Garza HJ, Bosques-Padilla FJ. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Revista de Gastroenterologia de Mexico 2012; 77(2): 82-90. [PubMed: 22672854]
Abstract
INTRODUCTION: Irritable bowel syndrome (IBS) is characterized by recurrent abdominal pain, bloating, and changes in bowel habit.
AIMS: To determine the clinical effectiveness of the antispasmodic agents available in Mexico for the treatment of IBS.
METHODS: We carried out a systematic review and meta-analysis of randomized controlled clinical trials on antispasmodic agents for IBS treatment. Clinical trials identified from January 1960 to May 2011 were searched for in MEDLINE, the Cochrane Library, and in the ClinicalTrials.gov registry. Treatment response was evaluated by global improvement of symptoms or abdominal pain, abdominal distention/bloating, and frequency of adverse events. The effect of antispasmodics vs placebo was expressed in OR and 95% CI.
RESULTS: Twenty-seven studies were identified, 23 of which fulfilled inclusion criteria. The studied agents were pinaverium bromide, mebeverine, otilonium, trimebutine, alverine, hyoscine, alverine/simethicone, pinaverium/simethicone, fenoverine, and dicyclomine. A total of 2585 patients were included in the meta-analysis. Global improvement was 1.55 (CI 95%: 1.33 to 1.83). Otilonium and the alverine/simethicone combination produced significant values in global improvement while the pinaverium/simethicone combination showed improvement in bloating. As for pain, 2394 patients were included with an OR of 1.52 (IC 95%: 1.28 a 1.80), favoring antispasmodics.
CONCLUSIONS: Antispasmodics were more effective than placebo in IBS, without any significant adverse events. The addition of simethicone improved the properties of the antispasmodic agents, as seen with the alverine/simethicone and pinaverium/simethicone combinations.
Copyright © 2011 Asociación Mexicana de Gastroenterología. Published by Elsevier España. All rights reserved.
- Review Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.[Cochrane Database Syst Rev. 2011]Review Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Cochrane Database Syst Rev. 2011 Aug 10; (8):CD003460. Epub 2011 Aug 10.
- Review Role of antispasmodics in the treatment of irritable bowel syndrome.[World J Gastroenterol. 2014]Review Role of antispasmodics in the treatment of irritable bowel syndrome.Annaházi A, Róka R, Rosztóczy A, Wittmann T. World J Gastroenterol. 2014 May 28; 20(20):6031-43.
- Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study.[Aliment Pharmacol Ther. 2010]Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study.Wittmann T, Paradowski L, Ducrotté P, Bueno L, Andro Delestrain MC. Aliment Pharmacol Ther. 2010 Mar; 31(6):615-24. Epub 2009 Dec 10.
- Alverine citrate, simeticone, and Rome III irritable bowel syndrome.[Aliment Pharmacol Ther. 2010]Alverine citrate, simeticone, and Rome III irritable bowel syndrome.Ford AC. Aliment Pharmacol Ther. 2010 Apr; 31(7):767-8; author reply 768-9.
- Review The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide.[Eur Rev Med Pharmacol Sci. 2012]Review The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide.Forte E, Pizzoferrato M, Lopetuso L, Scaldaferri F. Eur Rev Med Pharmacol Sci. 2012 Jan; 16(1):25-37.
- Effect of antispasmodic agents, alone or in combination, in the treatment of Irr...Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
Your browsing activity is empty.
Activity recording is turned off.
See more...